Bristol, SystImmune Phase III izalontamab brengitecan trial in metastatic TNBC meets dual primary endpoints
- Interim topline data showed statistically significant, clinically meaningful progression-free and overall survival improvements versus chemotherapy.
- Study evaluated antibody-drug conjugate izalontamab brengitecan in patients with previously treated metastatic triple-negative breast cancer.
- Izalontamab brengitecan is jointly developed by Bristol Myers Squibb and SystImmune as an antibody-drug conjugate therapy.
- RBC Capital initiated Bristol-Myers Squibb at Sector Perform with a $60 price target, citing depth of the late-stage pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.